Neurologic Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
Agnesrinky (talk | contribs) No edit summary |
Agnesrinky (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{CMG}} {{AE}} {{RAB}} | {{CMG}} {{AE}} {{RAB}} | ||
==Overview== | ==Overview== | ||
==Pathophysiology of Complications in the Nervous System== | |||
==Mechanism of targetting Nervous System== | |||
==Complications in Central Nervous System== | ==Complications in Central Nervous System== | ||
| Line 13: | Line 17: | ||
#Encephalopathy | #Encephalopathy | ||
#Headache | #Headache | ||
==Complications in Peripheral Nervous system== | ==Complications in Peripheral Nervous system== | ||
Revision as of 02:50, 12 June 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Rinky Agnes Botleroo, M.B.B.S.
Overview
Pathophysiology of Complications in the Nervous System
Mechanism of targetting Nervous System
Complications in Central Nervous System
- Cerebrovascular Accident/Stroke
- Hemorrhagic
- Ischaemic
- Acute Encephalitis
- Viral Meningitis
- Epileptic Seizures
- Encephalopathy
- Headache
Complications in Peripheral Nervous system
- Guillain-Barre syndrome
- Anosmia
- Acute Myelitis
- Miller Fischer Sydrome
- Polyneuritis Cranialis